[EN] SALT INDUCIBLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES INDUCTIBLES PAR UN SEL
申请人:MASSACHUSETTS GEN HOSPITAL
公开号:WO2022031928A1
公开(公告)日:2022-02-10
The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.
Role of benzimidazole (Bid) in the δ-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH2-Bid (UFP-502)☆
作者:Severo Salvadori、Stella Fiorini、Claudio Trapella、Frank Porreca、Peg Davis、Yusuke Sasaki、Akihiro Ambo、Ewa D. Marczak、Lawrence H. Lazarus、Gianfranco Balboni
DOI:10.1016/j.bmc.2007.12.032
日期:2008.3.15
H-Dmt-Tic-NH-CH2-Bid (UFP-502) was the first delta-opioid agonist prepared from the Dmt-Tic pharmacophore. It showed interesting pharmacological properties, such as stimulation of mRNA BDNF expression and antidepression. To evaluate the importance of 1H-benzimidazol-2-yl (Bid) in the induction of delta-agonism, it was substituted by similar heterocycles: The substitution of NH(1) by O or S transforms the reference delta-agonist into delta-antagonists. Phenyl ring of benzimidazole is not important for delta-agonism; in fact 1H-imidazole-2-yl retains delta-agonist activity. (C) 2007 Elsevier Ltd. All rights reserved.